Sunitinib is a multi-kinase inhibitor that targets VEGFR-1/2/3, PDGFRα/β, c-Kit, colony-stimulating factor 1 receptor (CSF1R), RET, and FLT3, it has been approved for treating renal cell carcinoma and imatinib-resistant gastrointestinal mesenchymal tumor (GIST) [76]. Here, CSF1R is linked to hereditary clear cell renal cell carcinoma.